Gad Getz

TL;DR: It is suggested that in NSCLC, a high number of nonsynonymous tumor mutations is associated with immune cell infiltration and inflammatory T-cell expression signatures, leading to increased sensitivity to PD-1/PD-L1 inhibition across PD-L 1 expression subgroups.

TL;DR: A longitudinal genomic investigation of 3 patients who, with daily exposure to ibrutinib, achieved partial remission and later experienced CLL progression, but not Richter’s transformation is described, indicating that all three patients lacked mutations in BTK and for the most part, in other genes in the BCR signaling pathway.

TL;DR: It is demonstrated that genomic events are at the root of virtually all tumors, with each carrying on average 4.6 driver events, and a whole-genome panorama of driver events across more than 2,500 tumors from 37 types of cancer is obtained.

TL;DR: A vast AE resource generated from the GTEx v8 release is presented and the utility of this resource is demonstrated, and an extension of the tool phASER is developed that allows effect sizes of cis -regulatory variants to be estimated using haplotype-level AE data.

TL;DR: This work extensively characterise intra-tumour heterogeneity (ITH) across 2,778 cancer whole genome sequences from 36 cancer types, demonstrating that nearly all tumours with sufficient sequencing depth contain evidence of recent subclonal expansions, and that most cancer types show clear signs of positive selection in both clonal and sub clonal protein coding variants.